Factor X Stockton: A mild bleeding diathesis associated with an active site mutation in factor X

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 1, 1996, Pages 5-14

  Messier, T L ^a   Wong, C Y ^b   Bovill, E G ^a   Long, G L ^a   Church, W R ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b St Joseph's Medical Center Stockton   (United States)

Author keywords

Bleeding disorders; Coagulation factor deficiency; Factor X; Genetic mutation

Indexed keywords

BLOOD CLOTTING FACTOR 10;

ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; GENE MUTATION; HUMAN; PRIORITY JOURNAL;

EID: 0029918581     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199601000-00001     Document Type: Article

References (27)

1. Royle NJ, Fung MR, MacGillivray RT, Hamerton JL. The gene for clotting factor X is mapped to 13q32→qter. Cytogenet Cell Genet 1986; 41: 185-188.
2. Scambler PJ, Williamson R. The structural gene for human coagulation factor X is located on chromosome 13q34. Cytogenet Cell Genet 1985; 39: 231-233.
3. Roberts HR, Lefkowitz JB. Inherited disorders of prothrombin conversion. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott, 1994; 200-218.
4. Santo Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88: 1685-1689.
5. Graham JB, Barrow EM, Hougie C. Stuart clotting defect. II. Genetic aspects of a 'new' hemorrhagic state. J Clin Invest 1957; 36: 497-503.
6. +14→Lys) and its functional consequences in a hereditary factor X deficiency (factor X 'Vorarlberg'). J Biol Chem 1990; 265: 11982-11989.
7. San Antonio. Blood 1989; 74: 1486-1490.
8. Friuli results from a substitution of serine for proline at position 343. Blood 1991; 77: 317-323.
9. Ouellette LA, Messier TL, Church WR. Neutralization of factor X activity by factor X-specific monoclonal antibodies. Blood Coag Fibrinol 1992; 3: 563-574.
10. Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982; 60: 59-63.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
12. Church WR, Mann KG. A simple purification of human factor X using a high affinity monoclonal antibody immunoadsorbant. Thromb Res 1985; 38: 417-424.
13. Bajaj SP, Mann KG. Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem 1973; 248: 7729-7741.
14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage t4. Nature 1970; 227: 680-685.
15. Laposata M, Connor AM, Hicks D, Phillips DK. The Clinical Hemostasis Handbook. Chicago: Year Book Medical Publishers, 1989; 67-71.
16. Blow DM, Birktoft JJ, Hartley BS. Role of a buried acid group in the mechanism of action of chymotrypsin. Nature 1969; 221: 337-340.
17. Barker D, Schafer M, White R. Restriction sites containing CpG show a higher frequency of polymorphism in human DNA. Cell 1984; 36: 131-138.
18. Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet 1988; 78: 151-155.
19. Messier TL, Pittman DD, Long GL, Kaufman RJ, Church WR. Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X. Gene 1991; 99: 291-294.
20. Titani K, Fujikawa K, Enfield DL, Ericsson LH, Walsh KA, Neurath H. Bovine factor X1 (Stuart factor): amino-acid sequence of the heavy chain. Proc Natl Acad Sci USA 1975; 72: 3082-3086.
21. Fersht A. Enzyme Structure and Mechanism. 2nd edn. New York: W. H. Freeman, 1985; 407.
22. Sprang S, Standing T, Fletterick RJ, et al. The three-dimensional structure of Asn102 mutant of trypsin: role of Asp102 in serine protease catalysis. Science 1987; 237: 905-909.
23. Craik CS, Roczniak S, Largman C, Rutter WJ. The catalytic role of the aspartic acid in serine proteases. Science 1987; 237: 909-913.
24. Carter P, Wells JA. Dissecting the catalytic triad of a serine protease. Nature 1988; 332: 564-568.
25. Taylor FB, Chang ACK, Peer GT, et al. DEGR-Factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78: 364-368.
26. Benedict CR, Ryan J, Todd J, et al. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood 1993; 81: 2059-2066.
27. 419). Protein Expr Purif 1992; 3: 518-524.